Charles River Laboratories International Inc.

354.36-0.9700-0.27%Vol 288.77K1Y Perf 96.64%
Jun 15th, 2021 16:00 DELAYED
BID350.00 ASK0.0000
Open355.47 Previous Close355.33
Pre-Market- After-Market354.36
 - -  - -%
Target Price
366.11 
Analyst Rating
Strong Buy 1.50
Potential %
3.32 
Finscreener Ranking
★★     47.22
Insiders Trans % 3/6/12 mo.
-100/-100/-96 
Value Ranking
★+     44.50
Insiders Value % 3/6/12 mo.
-100/-100/-95 
Growth Ranking
★★★★     60.05
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-94 
Income Ranking
 —    -
Market Cap17.81B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
98.96 
Earnings Date
4th Aug 2021

Today's Price Range

353.04356.35

52W Range

165.76356.35

5 Year PE Ratio Range

18.9054.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.44%
1 Month
7.69%
3 Months
22.82%
6 Months
47.55%
1 Year
96.64%
3 Years
202.23%
5 Years
326.32%
10 Years
805.60%

TickerPriceChg.Chg.%
CRL354.36-0.9700-0.27
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Financial StrengthValueIndustryS&P 500US Markets
1.30
1.80
0.52
1.10
5.50
Leverage Ratio 2.70
ProfitabilityValueIndustryS&P 500US Markets
37.20
18.40
26.20
15.00
12.41
RevenueValueIndustryS&P 500US Markets
3.04B
60.52
13.89
15.37
Earnings HistoryEstimateReportedSurprise %
Q01 20212.192.5315.53
Q04 20202.122.3912.74
Q03 20201.802.3329.44
Q02 20201.271.5824.41
Q01 20201.481.8424.32
Q04 20191.832.019.84
Q03 20191.641.693.05
Q02 20191.551.635.16
Earnings Per EndEstimateRevision %Trend
6/2021 QR2.337.87Positive
9/2021 QR2.452.94Positive
12/2021 FY9.998.71Positive
12/2022 FY11.328.64Positive
Next Report Date4th Aug 2021
Estimated EPS Next Report2.33
Estimates Count9
EPS Growth Next 5 Years %14.00
Volume Overview
Volume288.77K
Shares Outstanding50.25M
Trades Count6.65K
Dollar Volume107.54M
Avg. Volume483.60K
Avg. Weekly Volume282.84K
Avg. Monthly Volume575.91K
Avg. Quarterly Volume608.71K

Charles River Laboratories International Inc. (NYSE: CRL) stock closed at 354.36 per share at the end of the most recent trading day (a -0.27% change compared to the prior day closing price) with a volume of 290.22K shares and market capitalization of 17.81B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 18400 people. Charles River Laboratories International Inc. CEO is James C. Foster.

The one-year performance of Charles River Laboratories International Inc. stock is 96.64%, while year-to-date (YTD) performance is 41.82%. CRL stock has a five-year performance of 326.32%. Its 52-week range is between 165.76 and 356.35, which gives CRL stock a 52-week price range ratio of 98.96%

Charles River Laboratories International Inc. currently has a PE ratio of 47.70, a price-to-book (PB) ratio of 8.10, a price-to-sale (PS) ratio of 5.87, a price to cashflow ratio of 27.60, a PEG ratio of 2.32, a ROA of 6.61%, a ROC of 10.45% and a ROE of 19.03%. The company’s profit margin is 12.41%, its EBITDA margin is 26.20%, and its revenue ttm is $3.04 Billion , which makes it $60.52 revenue per share.

Of the last four earnings reports from Charles River Laboratories International Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.33 for the next earnings report. Charles River Laboratories International Inc.’s next earnings report date is 04th Aug 2021.

The consensus rating of Wall Street analysts for Charles River Laboratories International Inc. is Strong Buy (1.5), with a target price of $366.11, which is +3.32% compared to the current price. The earnings rating for Charles River Laboratories International Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Charles River Laboratories International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Charles River Laboratories International Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.66, ATR14 : 7.21, CCI20 : 138.50, Chaikin Money Flow : 0.01, MACD : 8.02, Money Flow Index : 73.72, ROC : 6.67, RSI : 66.00, STOCH (14,3) : 94.02, STOCH RSI : 0.75, UO : 66.22, Williams %R : -5.98), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Charles River Laboratories International Inc. in the last 12-months were: Birgit Girshick (Option Excercise at a value of $2 295 105), Birgit Girshick (Sold 21 918 shares of value $6 530 320 ), David R. Smith (Option Excercise at a value of $1 760 963), David R. Smith (Sold 29 945 shares of value $8 644 724 ), Deborah T. Kochevar (Sold 4 638 shares of value $1 002 934 ), George E. Massaro (Sold 5 313 shares of value $1 562 844 ), George M. Milne (Option Excercise at a value of $184 584), George M. Milne (Sold 3 530 shares of value $1 023 730 ), James C. Foster (Option Excercise at a value of $6 855 513), James C. Foster (Sold 145 240 shares of value $38 905 662 ), Joseph W. LaPlume (Option Excercise at a value of $1 075 979), Joseph W. LaPlume (Sold 15 474 shares of value $4 147 242 ), Michael Gunnar Knell (Option Excercise at a value of $604 692), Michael Gunnar Knell (Sold 5 393 shares of value $1 379 766 ), Richard F. Wallman (Buy at a value of $1 679 006), Stephen D. Chubb (Option Excercise at a value of $184 584), Stephen D. Chubb (Sold 2 658 shares of value $620 632 ), William D. Barbo (Option Excercise at a value of $307 559), William D. Barbo (Sold 6 800 shares of value $1 857 354 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (69.23 %)
9 (69.23 %)
10 (76.92 %)
Moderate Buy
1 (7.69 %)
1 (7.69 %)
0 (0.00 %)
Hold
3 (23.08 %)
3 (23.08 %)
3 (23.08 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.46

Charles River Laboratories International Inc.

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.

CEO: James C. Foster

Telephone: +1 781 222-6000

Address: 251 Ballardvale Street, Wilmington 01887, MA, US

Number of employees: 18 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

78%22%

Bearish Bullish

49%51%

Bearish Bullish

58%42%

News

Stocktwits